

Author's Accepted Manuscript

Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer

Raman AG, Sarma KV, Raman SS, Priester AM, Mirak SA, Riskin-Jones HH, Dhinagar N, Speier W, Felker E, Sisk AE, Lu D, Kinnaird A, Reiter RE, Marks LS, Arnold CW

DOI: [10.1097/JU.0000000000001832](https://doi.org/10.1097/JU.0000000000001832)

Reference: JU-21-28

To appear in: *The Journal of Urology*

Accepted Date: 09 April 2021

Please cite this article as: Raman AG, Sarma KV, Raman SS, Priester AM, Mirak SA, Riskin-Jones HH, Dhinagar N, Speier W, Felker E, Sisk AE, Lu D, Kinnaird A, Reiter RE, Marks LS, Arnold CW, Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer, *The Journal of Urology*® (2021), doi: [10.1097/JU.0000000000001832](https://doi.org/10.1097/JU.0000000000001832).

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer

Alex G. Raman MS^{1*}, Karthik V. Sarma MS^{1*}, Steven S. Raman MD¹, Alan M. Priester PhD^{2,3}, Sohrab Afshari Mirak MD¹, Hannah H. Riskin-Jones MSc¹, Nikhil Dhinagar PhD¹, William Speier PhD¹, Ely Felker MD¹, Anthony E. Sisk DO⁴, David Lu MD¹, Adam Kinnaird MD PhD^{2,5}, Robert E. Reiter MD², Leonard S. Marks MD², Corey W. Arnold PhD^{1,3,4}

¹ Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles

² Department of Urology, David Geffen School of Medicine, University of California, Los Angeles

³ Department of Bioengineering, David Geffen School of Medicine, University of California, Los Angeles

⁴ Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles

⁵ Division of Urology, Department of Surgery, University of Alberta

* Dual first authorship

Corresponding Author:

Corey W. Arnold, PhD
Director, Computational Diagnostics Lab
Professor of Radiological Sciences, Pathology & Laboratory Medicine, and Bioengineering
University of California, Los Angeles
924 Westwood Blvd, Ste 420
Los Angeles, CA 90024

United States
cwarnold@ucla.edu
(310) 794-3538

Word Count: 2997

ACCEPTED UNEDITED MANUSCRIPT

ABSTRACT

Purpose. The appropriate number of systematic biopsy cores to retrieve during Magnetic Resonance Imaging (MRI)-targeted prostate biopsy is not well defined. We aimed to demonstrate a biopsy sampling approach that reduces required core count while maintaining diagnostic performance.

Materials and Methods. We collected data from a cohort of 971 men who underwent MRI-ultrasound fusion targeted biopsy for suspected prostate cancer. A regional targeted biopsy (RTB) was evaluated retrospectively; only cores within 2 cm of the margin of a radiologist-defined region of interest (ROI) were considered part of the RTB. We compared detection rates for clinically significant prostate cancer (csPCa) and cancer upgrading rate on final whole mount pathology after prostatectomy between RTB, combined, MRI-targeted, and systematic biopsy.

Results. 16,459 total cores from 971 men were included in the study datasets, of which 1,535 (9%) contained csPCa. The csPCa detection rates for systematic, MRI-targeted, combined, and RTB were 27.0% (262 /971), 38.3% (372/ 971), 44.8% (435/971) and 44.0% (427/ 971) respectively. Combined biopsy detected significantly more csPCa than systematic and MRI-targeted biopsy ($p<0.001$, $p=0.004$ respectively), but was similar to RTB ($p=0.71$), which used on average 3.8 (22%) fewer cores per patient. In 102 patients who underwent prostatectomy, there was no significant difference in upgrading rates between RTB and combined biopsy ($p=0.84$).

Conclusions. A regional targeted biopsy approach can maintain state-of-the-art detection rates while requiring fewer retrieved cores. This result informs decision-making about biopsy site selection and total retrieved core count.

INTRODUCTION

The current gold standard for prostate cancer diagnosis involves a targeted biopsy of suspicious MRI regions of interest combined with a systematic template biopsy; together, they form a combined biopsy procedure consisting of, at our institution, an average of 17 retrieved biopsy cores.

When compared to MRI-targeted biopsy, systematic biopsy has been shown to detect higher rates of clinically insignificant cancer, defined using the International Society of Urological Pathology (ISUP) prostate cancer grading system as grade group 1, and lower rates of clinically significant cancer, defined as grade group ≥ 2 (these same grade group designations are used in this study).^{1,2} Nevertheless, combined biopsy is widely recommended since studies have shown that in 14-16% of patients who underwent both procedures and received a csPCa diagnosis, the csPCa was detected by systematic biopsy alone.^{3,4}

The combined biopsy approach requires obtaining significantly more biopsy cores than either systematic biopsy or MRI-targeted biopsy alone, increasing the cost, length, and discomfort of the procedure as well as the risk for sepsis, hematospermia, and pelvic and perineal pain.⁵⁻⁷ In order to reduce these risks, it is prudent to retrieve the minimal number of biopsy cores required to adequately assess the patient's current cancer status.

Although a precedent has been set establishing combined biopsy as the most robust prostate biopsy protocol⁸, no study to date has rigorously investigated the spatial relationship between systematic biopsy cores and MRI targets using the measured locations of obtained cores. As a result, little evidence is available to guide the determination of the optimal total number and location of biopsy cores that should be obtained from a patient; instead, most attention has been

focused on determining the appropriate number of cores sampled from each ROI in the targeted biopsy component.^{9–12}

Tschirdewahn et al. used a retrospective analysis to examine the use of a targeted saturation biopsy strategy in which biopsies were taken only from the MRI target and adjacent areas,¹³ an approach suggested in some scenarios by the Prostate Imaging – Reporting and Data System (PI-RADS) committee.¹⁴ This analysis found that restricting sampling to targeted locations within ROIs and systematic biopsy locations within adjacent Ginsburg sectors was superior to targeted or systematic biopsy alone. However, the true biopsy retrieval coordinates were not available to enable a complete analysis of the relationship between distance and yield. In addition, without prostatectomy data, upgrading and downgrading rates could not be assessed, making a full sensitivity assessment impossible.

In this study, we propose a biopsy site selection strategy which we refer to as “regional targeted biopsy.” This strategy optimizes the selection of additional biopsy sites by focusing on regions of the prostate located within the two-centimeter penumbra of a radiologist-designated ROI with a high suspicion index (i.e. PI-RADS score). Prior work that places MRI underestimation of prostate cancer tumors when compared to whole mount at a median of 13.5 mm per tumor, along with clinical intuition from the urologists and radiologists involved in this study helped inform the decision of using a 2-cm margin as the basis for constructing a RTB.¹⁵ A sensitivity analysis of this threshold choice is provided. We hypothesized that this strategy would achieve equivalent detection rates for clinically significant prostate cancer while requiring the retrieval of fewer biopsy cores.

In order to evaluate the potential impact of this strategy, we retrospectively calculated the results of a “regional targeted biopsy,” in which we discarded cores obtained from combined biopsy that are located outside of the two-centimeter ROI penumbra. This location assessment was enabled using a retrospective sensor fusion approach that provides the three-dimensional localization of each retrieved biopsy core within the prostate. We compared both csPCa detection rates across our entire cohort and grade group upgrading and downgrading rates of a subcohort who underwent radical prostatectomy across four different protocols: systematic biopsy, MRI-targeted biopsy, combined biopsy, and RTB.

MATERIALS AND METHODS

Study Inclusion and Exclusion Criteria

We retrospectively collected data from a cohort of patients at our institution who underwent standardized 3 Tesla multiparametric MRI followed by standardized MRI-ultrasound fusion combined (*both* systematic and targeted) biopsy using spatially localized targets on a single system with specialized fusion software (Artemis and Profuse; Eigen Inc, Grass Valley, California) between 2011 and 2018. Patients were included regardless of how many biopsies they may have had previous to the study period or their Prostate Specific Antigen (PSA) value; however, for patients with repeat biopsies during the study period, only the first biopsy session was included for analysis. To ensure a fair comparison of cancer detection rates, we chose to include only the subset of patients who received at least 10 systematic biopsy cores. This minimum threshold of 10 systematic cores was consistent with recommendations from the European Association of Urology and others.¹⁶⁻¹⁸ All MRI lesions were graded by one of three experienced genitourinary radiologists (SR, DL, and EF with 22, 29, and 5 years of domain-

specific experience respectively) using a published institutional score for lesions graded between 2011 and 2014 and the PI-RADS version 2 score for lesions graded between 2015 and 2018.¹⁹ The institutional score is a 1 to 5 Likert score based on quantitative metrics that has been shown to have a similar csPCa detection rate to PI-RADS version 2.²⁰ Patients were excluded from analysis if their biopsy procedure was performed under a clinical trial protocol to avoid confounding from protocol differences, and were also excluded from analysis if real-time positional data was corrupt or unavailable for one or more of their biopsy cores.

MRI and Biopsy Protocols

As a part of routine clinical interpretation, MRI target ROI contours were drawn on axial T2-weighted scans by one of three experienced genitourinary radiologists using commercially available annotation software (DynaCad; Invivo-Philips, Gainesville, Florida). To maximize specificity, the clinical annotation protocol required ROI margins to be drawn tightly around suspicious targets. These MRI annotations were then transferred to the MRI-ultrasound fusion device to enable the biopsy procedure. During the procedure, real-time sensor fusion was used to determine the three-dimensional spatial coordinates of the tip and base of each individual biopsy core retrieved, including both targeted and template cores. Patients were anesthetized using a periprostatic nerve block of 20cc 1% xylocaine, and all cores were retrieved by a single urologist (LSM) with 10 years of fusion biopsy experience. Computerized targeting guidance was provided for both systematic and targeted cores. For systematic cores, a target marker was designated on the procedural console and the operator retrieved a core from the designated location. For targeted cores, a radiologist-delineated ROI was displayed on the procedural console, and the operator retrieved cores from the ROI. Our combined biopsy protocol uses the “target + standard” approach for all biopsies, wherein targeted cores were taken before

systematic cores. All cores that were intended to be targeted at an ROI were designated as targeted cores and all cores that were intended to be systematic were designated as such, regardless of their position relative to the ROI. Cores were taken every 5 mm along the longest axis for irregularly-shaped ROIs, and in a cross-hair pattern for regularly shaped ROIs. The standard minimum number of cores per ROI was 2, though a single patient in our dataset received 1 core for their ROI.

All retrieved biopsy cores were interpreted by a subspecialized group of genitourinary pathologists with 5-15 years of experience in prostate cancer interpretation and assigned Gleason scores and grade groups.²¹ For the purposes of this study, clinically significant prostate cancer included any biopsy core assigned a ISUP grade group of 2 or higher.

Biopsy Distance Calculations

For each patient, the three-dimensional spatial coordinates corresponding to each biopsy core were retrieved. The distance between a targeted or systematic biopsy core and an ROI was determined by both a distance from the edge of the ROI and the distance from the centroid of the ROI. If multiple ROIs were present, the smallest distance of the core to any ROI was used.

To determine an individual biopsy core's distance from the edge of an ROI, we first used the ray-casting algorithm to determine if the core intersected the ROI.²² A distance of 0 was assigned to biopsy cores intersecting the ROI, while the shortest three-dimensional distance between the set of points representing the biopsy core and ROI margin was assigned to biopsy cores not intersecting the ROI. In addition to the distance from the edge, we computed the shortest three-dimensional distance between each core and the ROI centroid as an alternative distance metric.

Statistical Methods

To compare the cancer detection rates of systematic biopsy, MRI-targeted biopsy, combined biopsy, and RTB, as well as subsequent whole-mount grade group upgrading and downgrading of each of these methods, the two-tailed, two-proportion z-test was used. All tests were evaluated at a significance level of $p < 0.05$.

RESULTS

Patient Cohort

The initial study cohort included 1,705 patients. We excluded 239 patients with fewer than 10 systematic biopsy cores, 233 patients who participated in the Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer) PAIREDCAP clinical trial², and 262 patients due to missing biopsy core positional data. The final study cohort included 971 patients who underwent 3 Tesla multiparametric MRI and MRI-ultrasound fusion biopsy between April 2011 and December 2018 (Figure 1) with an average age, PSA level, and prostate volume of 64.5 ± 7.4 years, 8.4 ± 7.9 ng/ml, and 49.9 ± 24.2 cm³, respectively. (Table 1). The average ROI volume was 0.9 ± 2.2 cm³, and when the ROI volume was expanded by 2 cm, the average expanded ROI volume was 26.4 ± 9.0 cm³.

Of these 971 patients, 117 patients underwent prostatectomy after biopsy, and 855 were placed on active surveillance or received other medical treatment. For our prostatectomy subset analysis, we excluded 15 patients whose biopsies occurred more than a year before prostatectomy, yielding a final prostatectomy subcohort of 102 patients. This one-year cutoff was

chosen to align with our active surveillance protocol, in which repeat biopsy is not generally performed less than 12 months after the previous biopsy.

Biopsy Core Distance Analysis

In the primary analysis cohort of 971 patients, 16,459 cores were obtained, including 13,515 no cancer cores, 1,409 grade group 1 cores, 941 grade group 2 cores, 243 grade group 3 cores, 168 grade group 4 cores, and 183 grade group 5 cores. The cumulative proportion of cores with csPCa as a function of distance from the ROI is shown in Figure 2.

Biopsy Prostate Cancer Detection Rates

The cancer detection rates of different regional target penumbra sizes, as well as the number of cores saved for each size are shown in Table 2. Systematic, MRI-targeted, combined, and RTB (defined with a chosen 2 cm margin around the ROI) detected csPCa in 27.0% (262 /971), 38.3% (372/ 971), 44.8% (435/971) and 44.0% (427/ 971) of patients, respectively. Although combined biopsy detected significantly more patients with csPCa compared to systematic and MRI-targeted biopsy ($p<0.001$ and $p=0.004$, respectively), it detected a similar number of patients with csPCa to RTB ($p=0.71$). The RTB approach resulted in a 22.1% (3,644/16,459) decrease in the overall number of biopsy cores (an average of 3.8 cores per patient) when compared to combined biopsy (Figure 3, Table 1). MRI-targeted biopsy utilized an average of 3.97 cores per ROI while RTB, which expanded the ROI size, utilized an average of 10.58 cores per ROI.

The cancer detection rates of RTB, MRI-targeted, and systematic biopsy were additionally stratified by PI-RADS score and compared to combined biopsy (Table 3). RTB maintained a cancer detection rate above 95% (with the number of csPCa cases found by combined biopsy

used as ground truth) for PI-RADS 3, 4, and 5 cases while MRI-targeted biopsy improved steadily from 74.5% to 85.7% to 93.3% for PI-RADS 3, 4, and 5 respectively.

Systematic biopsy, MRI-targeted biopsy, combined biopsy, and RTB detected only cancer-negative cores in 434/971 (44.7%), 446/971 (45.9%), 323/971 (33.3%), and 353/971 (36.4%) patients, respectively and detected at most grade group 1 cancer in 275/971 (28.3%), 153/971 (15.8%), 213/971 (21.9%), and 191/971 (19.7%) patients, respectively. Combined and RTB detected only cancer-negative cores in a similar number of patients ($p = 0.15$) but significantly fewer than MRI-targeted and systematic biopsy ($p < 0.001$). Systematic biopsy detected significantly more grade group 1 prostate cancer compared to combined, MRI-targeted, and RTB ($p = 0.001$, $p < 0.001$, $p < 0.001$, respectively).

Locations of Positive Biopsies Outside MRI Targets

In 63 of 971 patients (6.5%) csPCa was detected only on systematic biopsy. In 8 of these 63 cases (12.7%), a systematic core that detected csPCa was greater than 2 cm from an MRI target (i.e. outside the regional penumbra). Every csPCa systematic core found for these 8 patients was of grade group 2. Of the 63 patients for whom systematic biopsy alone found csPCa, 18 had bilateral or midline targets and 45 had unilateral targets. Within the set of 45 patients with unilateral targets, csPCa was detected only ipsilateral to the target in 25 patients (55.6%), only contralateral to the target in 16 patients (35.6%), and both ipsilateral and contralateral to the target in 4 patients (8.9%). Entirely omitting contralateral biopsy would have thus missed csPCa in 16/971 patients (1.6%). The locations and grade groups of the positive cores found outside of unilateral MRI targets are shown in Table 4.

Whole Mount Histopathology Analysis

For the subcohort of 102 patients who underwent robotic prostatectomy and MRI-sectioned axial whole mount histopathology within a year of combined biopsy, 20.6% (21/102) and 12.7% (13/102) of patients were upgraded to grade groups ≥ 2 and ≥ 3 , respectively, when compared to the maximum grade group assigned to any retrieved biopsy core (i.e. any combined biopsy core). When only RTB cores within 2 cm of a target were included in the comparison, 25 (24.5%) and 14 (13.7%) were upgraded to grade group ≥ 2 and grade group ≥ 3 , respectively. These upgrading rates were not significantly different when compared to combined biopsy ($p=0.50$, $p=0.84$, respectively). When the upgrading results of MRI-targeted biopsy alone or systematic biopsy alone were compared to combined biopsy, all upgrading rates were significantly higher, except for the grade group 3 upgrading of MRI-targeted biopsy (19 vs. 13 cases, $p=0.25$). Downgrading on whole mount pathology occurred in relatively few cases without significant differences between biopsy protocols ($p>0.05$ for all comparisons).

DISCUSSION

An ideal prostate biopsy protocol would maximize the detection of csPCa using the fewest biopsy samples to optimize clinical utility while minimizing morbidity and cost. In this study, we used a retrospective analysis to evaluate a regional targeted biopsy strategy in which biopsy cores are only sampled from MRI targets (and their 2 cm margins) with a PI-RADS-related score of 3 or higher. We found that this optimized strategy performed similarly to combined biopsy in the detection of csPCa, while requiring significantly fewer biopsy cores (on average 3.8) per patient and 22% fewer cores overall.

In the entire study cohort, we found that 94.2% and 97.0% of grade group 2 or higher prostate cancers were detected even if cores retrieved more than 1.5 cm or 2 cm, respectively, from the edge of the MRI target were discarded. The high csPCa detection rate of cores in the penumbral region of MRI targets confirms the importance of the MRI-derived ROI as a hub of csPCa and supports the role of an institutional Likert and PI-RADS-based ROI scoring system as a predictor of underlying csPCa.^{23–25} This study also confirms that MRI-targets that are drawn for specificity can underestimate the true size and extent of tumor volumes.^{15,26} Our analysis of the relationship between RTB distance thresholds and the resulting cancer detection rates (Table 2) may also have implications for optimal margin size determination for focal therapy..

A major advantage of this study is the use of whole-mount histopathology data to indicate the ground truth presence of csPCa. We found that the prostate cancer upgrade rates after prostatectomy for combined biopsy and for RTB did not exhibit a statistically significant difference, despite the fewer biopsy cores used for the regional strategy. In contrast, systematic biopsy and MRI-targeted biopsy alone had significantly higher upgrade rates than combined biopsy. This aligns with other studies that show that combined biopsy demonstrates the fewest upgrades on prostatectomy compared to systematic and MRI-targeted, and that MRI-targeted biopsy tends to have fewer upgrades than systematic biopsy.^{8,27} Ultimately, the results of our whole-mount analysis suggest that a regional targeted biopsy can be an effective method for maximizing csPCa yield by achieving the sensitivity benefit of combined biopsy with fewer sampled cores.

One limitation of our work is the retrospective analytic approach we used to evaluate regional targeted biopsy. In this approach, we censored certain systematic cores based on a defined distance from the ROI as a stand-in for a true regional targeted biopsy. Thus, this study cannot

establish the prospective efficacy of a true regional targeted biopsy when compared to combined biopsy. Since systematic biopsy cores were obtained after targeted biopsy cores, it is also possible that the operator's knowledge of the target location may have influenced the placement of systematic cores. In addition, results are from a single tertiary institution with genitourinary MRI and pathology expertise, and all biopsy procedures were performed by a single urologist (LM) with significant MRI-ultrasound fusion biopsy experience; as such, our findings may not be representative of those obtained in other care settings. The real-time sensor fusion approach we used to determine biopsy core locations has a 2-3 mm registration uncertainty, which may have led to inaccuracies in the calculation of biopsy distances;²⁸ additionally, the designation of ROIs was done by a single radiologist for any given patient, and may be subject to inter-reader differences in boundary delineation.

CONCLUSIONS

We found that a regional targeted biopsy strategy had statistically similar sensitivity for clinically significant prostate cancer as a combined biopsy approach while requiring fewer cores, outperforming the MRI-targeted and systematic biopsy approaches alone. The success of the strategy was driven by the propensity of the most significant biopsy cores retrieved to be in the penumbral region of MRI targets with a PI-RADS-related score of 3 or higher. These findings can be useful to clinicians when determining the optimal set of biopsy locations for an individual patient and suggest that the regional targeted biopsy approach should be further evaluated as an alternative to combined MRI-targeted and systematic biopsy.

ACKNOWLEDGEMENTS

CWA acknowledges funding from NIH NCI R21 CA220352, NIH NCI P50 CA092131, and an NVIDIA Corporation Academic Hardware Grant. KVS acknowledges support from NCI F30CA210329, NIH NIGMS GM08042, and the UCLA-Caltech Medical Scientist Training Program. LSM acknowledges support from NIH NCI R01 CA195505 and R01 CA158627.

All data was used for this work under the approval of the UCLA Institutional Review Board (IRB #11-001580, #16-001087) and in compliance with HIPAA regulations. None of the sponsors of this study were involved in study design or performance, or in the writing or submission of this manuscript.

LSM and AMP report a financial interest in Avenda Health outside the submitted work. No other authors have competing interests to disclose.

REFERENCES

1. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med*. 2018;378(19):1767-1777.
2. Elkhoury FF, Felker ER, Kwan L, et al. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive. *JAMA Surg*. 2019;154(9):811.
3. Hanna N, Wszolek MF, Mojtahed A, et al. Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves but Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer. *J Urol*. 2019;202(5):944-951.
4. Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. *Lancet Oncol*. 2019;20(1):100-109.
5. Simsir A, Kismali E, Mammadov R, et al. Is It Possible to Predict Sepsis, the Most Serious Complication in Prostate Biopsy? *Urol Int*. 2010;84(4):395-399.
6. Berger AP, Gozzi C, Steiner H, et al. Complication rate of transrectal ultrasound guided prostate biopsy: A comparison among 3 protocols with 6, 10 and 15 cores. *J Urol*. 2004;171(4):1478-1481.
7. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic Review of Complications of Prostate Biopsy. *Eur Urol*. 2013;64(6):876-892.
8. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. *N Engl J Med*. 2020;382(10):917-928.

9. Tracy CR, Flynn KJ, Sjoberg DD, et al. Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores. *Urol Oncol Semin Orig Investig*. Published online 2020.
10. Kenigsberg AP, Renson A, Rosenkrantz AB, et al. Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy. *Eur Urol Oncol*. 2018;1(5):418-425.
11. Sonmez G, Demirtas T, Tombul ST, et al. What is the ideal number of biopsy cores per lesion in targeted prostate biopsy? *Prostate Int*. 2020;8(3):112-115.
12. Lu AJ, Syed JS, Ghabili K, et al. Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy. *Eur Urol*. 2019;76(1):14-17.
13. Tschirdewahn S, Wiesenfarth M, Bonekamp D, et al. Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography–fusion Biopsy. *Eur Urol Focus*. Published online July 11, 2020.
14. Padhani AR, Weinreb J, Rosenkrantz AB, et al. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. *Eur Urol*. 2019;75(3):385-396.
15. Priester A, Natarajan S, Khoshnoodi P, et al. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. *J Urol*. 2017;197(2):320-326.

16. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*. 2017;71(4):618-629.
17. Presti JC. Prostate biopsy: how many cores are enough? *Urol Oncol Semin Orig Investig*. 2003;21(2):135-140.
18. Hu Z, Wang J, Sun D, et al. How Many Cores Does Systematic Prostate Biopsy Need?: A Large Sample Retrospective Analysis. *J Ultrasound Med*. 2019;38(6):1491-1499.
19. Sonn GA, Natarajan S, Margolis DJA, et al. Targeted Biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic Resonance Ultrasound Fusion Device. *J Urol*. 2013;189(1):86-92.
20. Mirak SA, Bajgirani AM, Hosseiny M, et al. Comparison of Performance of PI-RADSv2 and a Quantitative PI-RADSv1 Based Protocol in 3T Multiparametric MRI for Detection, Grading and Staging of Prostate Cancer Using Whole Mount Histopathology as Reference Standard in 569 patients. In: *Proceedings of the American Urological Association Annual Meeting*. ; 2019.
21. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol*. 2015;40(2):1.
22. Roth SD. Ray casting for modeling solids. *Comput Graph Image Process*. 1982;18(2):109-144.

23. Rosenkrantz AB, Babb JS, Taneja SS, et al. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection. *Radiology*. 2017;283(1):119-129.
24. Filson CP, Natarajan S, Margolis DJA, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. *Cancer*. 2016;122(6):884-892.
25. Mehralivand S, Bednarova S, Shih JH, et al. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. *J Urol*. 2017;198(3):583-590.
26. Priester A, Elkhoury F, Vandell J, et al. Targeted Prostate Biopsy: Cancer Extends Beyond the ROI! In: *Proceedings of the American Urological Association Annual Meeting*. Vol 199. ; 2018.
27. Demirtaş A, Sönmez G, Tombul ŞT, et al. Comparison of the Upgrading Rates of International Society of Urological Pathology Grades and Tumor Laterality in Patients Undergoing Standard 12-Core Prostate Biopsy versus Fusion Prostate Biopsy for Prostate Cancer. *Urol Int*. 2019;103(3):256-261.
28. Marks L, Young S, Natarajan S. MRI–ultrasound fusion for guidance of targeted prostate biopsy. *Curr Opin Urol*. 2013;23(1):43-50.

ABBREVIATIONS

csPCa – Clinically Significant Prostate Cancer

MRI – Magnetic Resonance Imaging

PI-RADS – Prostate Imaging Reporting and Data System

ROI – Region of Interest

RTB – Regional Targeted Biopsy

ACCEPTED UNEDITED MANUSCRIPT

FIGURE LEGENDS

Figure 1. Patient Exclusion Criteria. The initial study cohort of 1,705 patients underwent combined biopsy at our institution. Patients were excluded if they received a systematic biopsy with fewer than ten cores, if they were subjects in the PAIREDCAP trial, or if they were missing coordinates for one or more biopsy cores. The primary distance analysis set therefore includes 971 patients. Among these 971 patients, 102 underwent prostatectomy less than a year after biopsy and were included in the prostatectomy subset.

Figure 2. Cancer Capture with Distance from the ROI. The proportion of cores found within varying distances of the edge of the closest ROI and the centroid of the closest ROI is shown, stratified by grade group. 94.2% and 97.0% of grade group 2 or higher cores are found within 1.5 cm and 2 cm of the *edge* of the ROI, respectively. 86.8% and 92.7% of grade group 2 or higher cores are found within 1.5 cm and 2 cm of the ROI *centroid*, respectively.

Figure 3. Expanded Three-Dimensional ROI for Regional Targeted Biopsy. Three-dimensional representation of a patient's prostate with the original (left) radiologist-derived ROI (maroon) and regional target (right) covering 20 millimeters (mm) in all directions from the edges of the ROI.

Figure 4. Upgrading and Downgrading of csPCa Diagnosis After Robotic Prostatectomy. The highest grade group from the biopsy and subsequent prostatectomy grade group were compared. The upgrading and downgrading of these grade groups for each of the four biopsy methods is shown, using the whole mount prostatectomy as ground truth.

TABLE LEGENDS

Table 1. Clinical and Demographic Information for both Patient Cohorts. Average age, PSA, prostate volume, and number of targeted, systematic, combined biopsy, and RTB cores are presented with their standard deviations. All other values are presented with their corresponding percentage of the cohort listed in parentheses.

Table 2. Cancer Detection Rates of RTB with Varying Penumbra Size. The cancer detection rates of regional targeted biopsy with an increasing ROI margin is shown, along with the average number of cores saved relative to combined biopsy. The P-value represents the results of a two proportion z-test comparing the cancer detection rate of each regional targeted biopsy method with combined biopsy.

Table 3. Cancer Detection Rates of RTB, MRI-targeted, Sytematic, and Combined Biopsy by PI-RADS Score. The number of csPCa cases found by each of the four biopsy methods discussed are stratified by PI-RADS scores. The number in parentheses shows each biopsy method's number of csPCa cases detected as a percentage of the total number of csPCa cases detected by combined biopsy for that PI-RADS score.

Table 4. Grade Groups of Positive Cores Found Outside Unilateral MRI Targets. Positive core counts in each group are presented; all cores originate from the 45 patients who had only ipsilateral MRI targets and positive cores outside of those targets. Four of these patients had both ipsilateral and contralateral positive cores, which have been allocated to the appropriate columns.

Table 1. Clinical and Demographic Information for both Patient Cohorts. Average age, PSA, prostate volume, and number of targeted, systematic, combined biopsy, and simulated regional targeted biopsy cores are presented with their standard deviations. All other values are presented with their corresponding percentage of the cohort listed in parentheses.

Attribute	All Patients (N = 971)	Prostatectomy (N = 102)
Age (years)	64.5 ± 7.4	62.2 ± 6.1
Race		
Caucasian	616 (63.4%)	72 (70.6%)
Asian	54 (5.6%)	6 (5.9%)
African American	37 (3.8%)	4 (3.9%)
Hispanic	22 (2.3%)	3 (2.9%)
American Indian	1 (0.1%)	0
Mixed	1 (0.1%)	0
Other	19 (2.0%)	2 (2.0%)
Unknown	221 (22.8%)	15 (14.7%)
PSA (ng/ml, normal <4)	8.4 ± 7.9	8.2 ± 6.8
Prostate Volume (cm ³)	60.8 ± 29.1	46.5 ± 18.1
ROI Volume (cm ³)	0.9 ± 2.2	0.7 ± 0.9
Regional Targeted ROI Volume (cm ³)	26.4 ± 9.0	23.4 ± 7.3
Maximum ROI Score		
3	415 (42.7%)	34 (33.0%)
4	380 (39.1%)	37 (36.2%)
5	176 (18.1%)	31 (30.4%)

Previous Biopsy		
No Previous Biopsy	309 (31.8%)	39 (38.2%)
1 Previous Biopsy	413 (42.5%)	41 (40.2%)
> 1 Previous Biopsy	246 (25.3%)	22 (21.6%)
Unknown	3 (0.3%)	0
Number of Targets	1.3 ± 0.6	1.4 ± 0.6
Number of Targeted Cores	5.0 ± 1.9	5.2 ± 1.9
Number of Systematic Cores	11.9 ± 1.1	11.6 ± 0.9
Number of Combined Biopsy Cores	17.0 ± 2.0	16.8 ± 1.9
Number of Simulated Regional Targeted Cores	13.2 ± 1.5	13.8 ± 3.5
Number of csPCa Targeted Cores	1.0 ± 1.7	2.0 ± 1.7
Number of csPCa Systematic Cores	0.5 ± 1.2	1.2 ± 1.4
Number of csPCa Combined Biopsy Cores	1.6 ± 2.5	3.2 ± 2.6
Number of csPCa Simulated Regional Targeted Cores	1.5 ± 2.5	3.1 ± 2.6

Table 2. Cancer Detection Rates of RTB with Varying Penumbra Size. The cancer detection rates of regional targeted biopsy with an increasing ROI margin is shown, along with the average number of cores saved relative to combined biopsy. The P-value represents the results of a two-proportion z-test comparing the cancer detection rate of each regional targeted biopsy method with combined biopsy.


RTB Penumbra Distance (mm)	Patients with csPCa Found	Proportion of Total csPCa Patients Detected	Average Number of Fewer Cores Relative to Combined Biopsy	Pval for RTB vs. Combined
5	396	0.91	9.658	0.074
10	413	0.949	7.45	0.314
15	421	0.968	5.501	0.522
20	427	0.982	3.753	0.715
25	432	0.993	2.211	0.891
30	434	0.998	1.064	0.964

Table 3. Cancer Detection Rates of RTB, MRI-targeted, Systematic, and Combined Biopsy by PI-RADS Score. The number of csPCa cases found by each of the four biopsy methods discussed are stratified by PI-RADS scores. The number in parentheses shows each biopsy method's number of csPCa cases detected as a percentage of the total number of csPCa cases detected by combined biopsy for that PI-RADS score.



PIRADS	RTB (2 cm) csPCa Detection	MRI-Targeted csPCa Detection	Systematic csPCa Detection	Combined Biopsy csPCa Detection
3	105 (95.5%)	82 (74.5%)	69 (62.7%)	110
4	173 (98.9%)	150 (85.7%)	111 (63.4%)	175
5	149 (99.3%)	140 (93.3%)	82 (54.7%)	150



Table 4. Grade Groups of Positive Cores Found Outside Unilateral MRI Targets. Positive core counts in each group are presented; all cores originate from the 45 patients who had only ipsilateral MRI targets and positive cores outside of those targets. Four of these patients had both ipsilateral and contralateral positive cores, which have been allocated to the appropriate columns.

Gleason Group	Ipsilateral Lesions (N = 37)	Contralateral Lesions (N = 25)
Group 2	28	23
Group 3	4	2
Group 4	4	0
Group 5	1	0




ACCEPTED UNEDITED MANUSCRIPT





- Prostate Capsule
- ROI
- Biopsy Core
- Expanded ROI (2 cm)



*Simulated Regional Targeted biopsy only includes cores within 2 cm of a target for biopsy cancer grading